Genomics in multiple sclerosis

被引：8
作者：
Habek, Mario [1 ,2 ,3 ]
Borovecki, Fran [1 ,2 ,4 ]
Brinar, Vesna V. [1 ,2 ,3 ]
机构：
[1] Univ Zagreb, Sch Med, Dept Neurol, Zagreb 41001, Croatia
[2] Univ Hosp Ctr Zagreb, Zagreb 41001, Croatia
[3] Univ Zagreb, Sch Med, Refferal Ctr Demyelinating Dis Cent Nervous Syst, Zagreb 41001, Croatia
[4] Ctr Translat & Clin Res, Dept Funct Genom, Zagreb, Croatia
来源：
CLINICAL NEUROLOGY AND NEUROSURGERY | 2010年 / 112卷 / 07期
关键词：
Multiple sclerosis; Biomarkers; Genomics; Microarrays; APPEARING WHITE-MATTER; GENE-EXPRESSION; MICROARRAY ANALYSIS; INTERFERON-BETA; LESIONS; CDNA; DISEASE;
D O I：
10.1016/j.clineuro.2010.03.028
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Multiple sclerosis (MS) is chronic, inflammatory disease of the central nervous system that mainly affects young adults and is characterized with dissemination of demyelinating lesions in time and space. It is well known that MS is very heterogeneous disease, so biomarkers that would reliably determine disease course, outcome or treatment response in early stages of the disease (preferentially clinically isolated syndrome) are desperately needed. Genome-wide expression analysis represents the profile of all genes in a certain tissue or cell population in a certain time point. Therefore, as the sequence of the human genome is entirely known, it is possible to analyze any given human gene in any given context. This review will discuss results and possible applications of genome-wide expression studies in brain tissue and blood samples of MS patients. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码：621 / 624
页数：4
相关论文
共 35 条
[1]   Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity [J].
Achiron, A ;
Gurevich, M ;
Friedman, N ;
Kaminski, N ;
Mandel, M .
ANNALS OF NEUROLOGY, 2004, 55 (03) :410-417
[2]   Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis [J].
Anat, Achiron ;
Anna, Feldman ;
Michael, Gurevich .
DISEASE MARKERS, 2009, 27 (02) :63-73
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression [J].
Barrett, JC ;
Kawasaki, ES .
DRUG DISCOVERY TODAY, 2003, 8 (03) :134-141
[5]   Development of biomarkers in multiple sclerosis [J].
Bielekova, B ;
Martin, R .
BRAIN, 2004, 127 :1463-1478
[6]   Gene expression profile in multiple sclerosis patients and healthy controls:: identifying pathways relevant to disease [J].
Bomprezzi, R ;
Ringnér, M ;
Kim, S ;
Bittner, ML ;
Khan, J ;
Chen, YD ;
Elkahloun, A ;
Yu, AM ;
Bielekova, B ;
Meltzer, PS ;
Martin, R ;
McFarland, HF ;
Trent, JM .
HUMAN MOLECULAR GENETICS, 2003, 12 (17) :2191-2199
[7]   Minimum information about a microarray experiment (MIAME) - toward standards for microarray data [J].
Brazma, A ;
Hingamp, P ;
Quackenbush, J ;
Sherlock, G ;
Spellman, P ;
Stoeckert, C ;
Aach, J ;
Ansorge, W ;
Ball, CA ;
Causton, HC ;
Gaasterland, T ;
Glenisson, P ;
Holstege, FCP ;
Kim, IF ;
Markowitz, V ;
Matese, JC ;
Parkinson, H ;
Robinson, A ;
Sarkans, U ;
Schulze-Kremer, S ;
Stewart, J ;
Taylor, R ;
Vilo, J ;
Vingron, M .
NATURE GENETICS, 2001, 29 (04) :365-371
[8]   Genomics in multiple sclerosis - Current state and future directions [J].
Comabella, Manuel ;
Martin, Roland .
JOURNAL OF NEUROIMMUNOLOGY, 2007, 187 (1-2) :1-8
[9]   Relapses and progression of disability in multiple sclerosis. [J].
Confavreux, C ;
Vukusic, S ;
Moreau, T ;
Adeleine, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) :1430-1438
[10]  
Cunnea P., 2009, Acta Neuropathol
1234